Both cpVD and wiVD had significant correlation with MD, average RNFL thickness, and average GCC thickness (p < 0.05 for all).
It is worth mentioning that we found the diagnostic ability of cpVD to be similar to that of wiVD.
Caption: Figure 2: Box plots showing the retinal vessel density and thickness in nonarteritic ischemic optic neuropathy (NAION) eyes and healthy control (HC) eyes: (a) whole enface image vessel density (wiVD), circumpapillary vessel density (cpVD), and parafoveal vessel density (pfVD); (b) average retinal nerve fiber layer (RNFL) thickness and average ganglion cell complex (GCC) thickness.
Biomarkers can indicate several health or disease characteristics and they were found to be useful in order to improve diagnosis, prevention strategies, and treatment options in the field of CPVD. In fact, biomarkers may be used to better identify high-risk individuals, to diagnose disease conditions promptly and accurately, and to effectively prognosticate and treat patients with disease, targeting also specific biological sites.
As such, the present issue deals with both reviews and research articles focused on novel applications of biomarkers used to enhance the ability of the clinician to optimally manage the patient with CPVD. Furthermore, this special issue will discuss breakthrough biological and technological developments in biomarkers identification which are expected to revolutionize clinical research environments and healthcare in the area of CPVD.